Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ABX464 in Healthy Japanese Volunteers
NCT05032560Phase 1Completed
- Sponsor
- Abivax
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of obefazimod in ulcerative colitis (UC) (4 arms), sponsored by Abivax. Primary endpoints: Incidence of adverse events (AEs) and SAEs at 6 weeks, Incidence of treatment-emergent serious adverse events at 6 weeks and 2 more. Started Sep 2021; status: completed.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05032560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032560.